SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical ...

As lentiviral vector (LVV) programs advance toward larger clinical trials and commercialization, manufacturing platforms and analytical strategies must evolve together. In this joint webinar, Minaris ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

Developed in collaboration with Korea's top clinical and hospital network, the integrated platform combines globally ...

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Plasmid DNA and Viral Vector Manufacturing Services With over 20 years of plasmid DNA and viral vector ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral ...